Home›Trial›NCT07085091
🔬NCT07085091Phase 1RECRUITING

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Study Summary

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)HNSCCCRC (Colorectal Cancer)ESCCColo-rectal CancerHead and Neck CancerEsophageal Squamous Cell Carcinoma (ESCC)
Interventions / Drugs
ALX2004ALX2004ALX2004
View on ClinicalTrials.gov ↗
Sponsor
ALXO
ALX Oncology
Oncology
D36/100
Study Details
Enrollment170 participants
Primary Completion—
Lead SponsorALX Oncology Inc.
Data Retrieved2026-04-11 02:53:29.486931+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.